Analysts have been eager to weigh in on the Healthcare sector with new ratings on Constellation Pharmaceuticals (CNST) and Surgalign Holdings (SRGA).

Constellation Pharmaceuticals (CNST)

Oppenheimer analyst Jay Olson maintained a Hold rating on Constellation Pharmaceuticals yesterday and set a price target of $24.00. The company’s shares closed last Monday at $19.76, close to its 52-week low of $17.00.

According to TipRanks.com, Olson is a 3-star analyst with an average return of 3.4% and a 47.7% success rate. Olson covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals, Crispr Therapeutics AG, and Frequency Therapeutics.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Constellation Pharmaceuticals with a $47.40 average price target.

See today’s analyst top recommended stocks >>

Surgalign Holdings (SRGA)

BTIG analyst Ryan Zimmerman maintained a Buy rating on Surgalign Holdings yesterday and set a price target of $3.00. The company’s shares closed last Monday at $1.70, close to its 52-week low of $1.46.

According to TipRanks.com, Zimmerman is a top 100 analyst with an average return of 36.1% and a 65.2% success rate. Zimmerman covers the Healthcare sector, focusing on stocks such as Tactile Systems Technology, Organogenesis Holdings, and Staar Surgical Company.

Currently, the analyst consensus on Surgalign Holdings is a Moderate Buy with an average price target of $3.50, representing a 98.9% upside. In a report issued on April 27, JMP Securities also maintained a Buy rating on the stock with a $4.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on SRGA:



Source link